Faeth Therapeutics, Inc. Deferred Federal Income Tax Expense (Benefit)
Faeth Therapeutics, Inc. (FTH) reported Deferred Federal Income Tax Expense (Benefit) of -$3.41 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-03-30
- Faeth Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was -$3.41M.
- Faeth Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was -$5.56M.
- Faeth Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2023 was -$5.75M.
- Faeth Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was -$10.35M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$3.41M 10-K · filed 2026-03-30 |
| 2024-12-31 | -$5.56M 10-K · filed 2026-03-30 |
| 2023-12-31 | -$5.75M 10-K · filed 2025-03-28 |
| 2022-12-31 | -$10.35M 10-K · filed 2024-02-29 |
| 2021-12-31 | -$6.60M 10-K · filed 2023-03-29 |
| 2020-12-31 | -$2.10M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |